Tenderwize
Zurück zur Suche

Non-exclusive rebate agreement for Filgrastim

GWQ ServicePlus AG·Düsseldorf, Germany·Deadline Nov 10, 2027 · 441 days left·Open·Supplies
Registrieren zum Speichern
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130 a Abs. 8 SGB V mit dem Wirkstoff Filgrastim.

46/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Warum diese Bewertung?

Chance

46 / 100

Komplexität

58 / 100

Risikofaktoren

Submission is not electronic and the notice indicates postal submission; missing or late physical delivery could invali...

Important procurement documents are referenced on the portal but were not included in the provided extracted text, so f...

No procurement documents available

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until Dec 2027
  • Supply of pharmaceutical products, specifically rebate agreements for Filgrastim.
  • Conclusion of non-exclusive rebate agreements under § 130a Abs. 8 SGB V.
Vollständige Zusammenfassung anzeigen

Open procedure notice for a pharmaceutical supply arrangement in Germany concerning non-exclusive rebate agreements for the active substance Filgrastim. The notice indicates a join-at-any-time model for interested pharmaceutical companies, with contract start planned for 2026-01-01 and a submission/mailing deadline for signed documents on 2025-12-10 to enable first notification on 2026-01-01. No contract value is stated. Submission is not electronic and appears to be postal. Procurement documents are referenced on the GWQ portal, but only the XML notice text was provided for analysis.

Risiken

Submission is not electronic and the notice indicates postal submission; missing or late physical delivery could invali...

Important procurement documents are referenced on the portal but were not included in the provided extracted text, so f...

No procurement documents available

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Signed contract in duplicate.
  • Proof of marketing authorization via extract from the public part of the AMIce database.

Administrative

  • Signed self-declaration (Annex 3).

Auftraggeber

Ort

Düsseldorf, DEU

Auftraggeberprofil

Profil öffnen

Kennung

DE258895210

Tätigkeit

Health

Lose (1)

LOT-0000

Non-exclusive rebate agreement for Filgrastim

Single lot for concluding non-exclusive rebate agreements under § 130a(8) SGB V for the active substance Filgrastim. The model is described as open to all interested pharmaceutical companies on equal terms during the contract term. The notice says participating sickness funds may vary by specialist lot, but only one lot is structured here and no separate lot breakdown is provided in the structured data.

SuppliesEU fundedElectronic submission

Ort

DEA11, Germany

Dauer

Dec 2025 - Dec 2027

Kategorie

Pharmaceutical products

Frist

Deadline Nov 10, 2027

Vergabedetails

Veröffentlichungsdatum
17 Nov 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
765198-2025

Ähnliche Ausschreibungen

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3